INTRODUCTION
Worldwide, the prevalence of childhood overweight and obesity increased from 4.2% in 1990 to 6.7% in 2010. 1 Children who are overweight or obese are more likely to be overweight in adulthood and to suffer from obesity-related morbidity and mortality. 2, 3 The obesity epidemic has been primarily attributed to changes in dietary and physical activity behaviors; 4, 5 however, exposure to estrogen-mimicking compounds during developmentally sensitive periods may contribute. 6, 7 Estrogenic agents can affect adipogenesis in vitro. 17-β Estradiol has resulted in increased preadipocyte proliferation, likely though upregulation of PPAR-γ. 8 Preadipocyte formation can occur as early as the blastocyst stage, 9 although upregulation of mesenchymal stem cell recruitment to preadipocytes is highest in the second trimester of pregnancy. 10 In a previous study of the association between oral contraceptive (OC) and diethylstilbestrol use in pregnancy and offspring obesity, 11 the strongest magnitude of association for OCs was in months 1 and 2, and for diethylstilbestrol in months 3-4. This study was executed at a time when the potency of OCs was considerably stronger (1959) (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) .
Experiments in animal models have shown a positive association between in utero and neonatal exogenous estrogen exposure and metabolic disruption in the offspring, including offspring overweight or obesity. 6, 7 However, in utero exposure to androgens has also been associated with offspring obesity. [12] [13] [14] Hormonal contraceptives can be androgenic, depending on the progestin component included. 15 The developmental effects of exogenous sex hormones on growth may be sex dependent, with associations primarily in male offspring. 16 The maternal metabolic milieu is also associated with offspring overweight or obesity. 17, 18 Hormonal contraceptives have, for many women, unintended metabolic effects, including elevated levels of very low-density lipoprotein cholesterol and total triglycerides. 15, [19] [20] [21] Hormonal contraceptives increase plasma insulin and cortisol, 21 and induce a state of insulin resistance. 15, 19, 20 Some of these metabolic changes, including increased total cholesterol 22 and insulin resistance, 23 are similar to those in women who are overweight or obese. Whether these metabolic effects persist after cessation of use is unclear; however, more androgenic formulations may subsequently increase risk of gestational diabetes. 24 The half-lives of hormonal contraceptives are generally o24 h; 25 however, in some instances drug components may be detectable for several months post cessation. For example, medroxyprogesterone acetate has been detectable in serum at 8 months post cessation of administration. 15 Previous hormonal contraceptive use may have long-term effects on endogenous hormone levels, including altered hormone levels both during pregnancy 26 and after menopause. 27 Given the data suggesting that hormonal compounds cause changes in follicular, 28, 29 embryonic and fetal development, 30, 31 that they may cause an obesity-like metabolic milieu 32 and that they may exert long-term effects on endogenous sex hormone levels, 27, 33 additional studies of hormonal contraceptive exposure and offspring development in humans are needed.
Because use of pharmacologic sex hormones in early pregnancy is relatively uncommon, most cohort studies lack the power to evaluate the association. Hormonal contraceptive failure occurs in about 3% of users. 34 With over 40 000 children followed to age 3, the Norwegian Mother and Child Cohort Study (MoBa) 35 offers an unusual opportunity to assess the influence of in utero exposure to exogenous sex hormones, through hormonal contraceptive use in early pregnancy, on childhood overweight or obesity. In the present study, through linkage of MoBa data with the Norwegian Prescription Registry (NorPD), we evaluated the association between hormonal contraceptive use and offspring overweight or obesity at 36 months of age.
MATERIALS AND METHODS
MoBa study participants were recruited in Norway from 1999 through 2008, as described in detail elsewhere. 35 Women were identified for eligibility when scheduling the routine prenatal ultrasound offered free of charge to all pregnant women in Norway at 17-20 weeks of gestation. Women were mailed an invitation to participate before the scheduled ultrasound, with informed consent and enrollment taking place at the ultrasound examination. Approximately 42% of all pregnant women in Norway were invited to participate in the study. Of these, 39% consented to participate. At enrollment, participants were asked to complete a selfadministered questionnaire to collect data on demographic characteristics, reproductive health history, disease and medication history, lifestyle factors and socioeconomic status. Follow-up is conducted through selfadministered questionnaires.
Prescription data from NorPD contains individual-level data on all medications prescribed and dispensed through pharmacies to noninstitutionalized individuals in Norway. By Norwegian law, as of 1 January 2004, all pharmacies must provide electronic data for all prescriptions dispensed. Data quality measures are in place for assuring the NorPD is accurate and complete. 36 A validation study of hormonal contraceptive use in the NorPD was conducted in adolescents and indicated a sensitivity of 99% and a specificity of 76% for the NorPD as compared with self-reported use. 37 In adolescents, hormonal contraceptives may be provided at no cost to the individual, but in adults, hormonal contraceptives are not a reimbursable prescription. This may increase the likelihood that a dispensed prescription will be used by the individual.
There were 107 308 MoBa pregnancies registered in the Medical Birth Registry of Norway (MBRN). All MBRN data are collected on a standardized birth notification form completed by the midwife or physician attending the birth. For the present analysis, we included pregnancies resulting in a singleton live birth, with no record of death in the first year of life, and with no documentation, on either the MoBa 17-week questionnaire or the MBRN, of having received infertility treatment for the index pregnancy. We additionally excluded pregnancies to women with prepregnancy chronic hypertension (n = 527). As the NorPD registry was not initiated until 1 January 2004, we further restricted our study population to pregnancies of women enrolled at least 12 months after the date on which the NorPD registry began collection of data (n = 48 615). For the primary analyses, we also excluded pregnancies with missing covariate data (n = 3966) and for loss to follow-up at age 3 (n = 24 997). The final study population included 19 652 pregnancies to 18 759 women (17 867 women with one offspring in the cohort, 1782 with two and 1 with three offspring) (Figure 1 ). The University of North Carolina at Chapel Hill, the National Institute of Environmental Health Sciences Institutional Review Board and the Norwegian Southeastern Regional Ethics Committee reviewed and approved this study.
Hormonal contraceptive use, before conception and in early pregnancy, was characterized according to the Anatomical Therapeutic Chemical Classification System. 38 We characterized exposure by type and route of administration (combination OC, progestin-only OC, vaginal ring, transdermal, injectable, implant and hormonal-based intrauterine device) and by progestin formulation. All hormonal contraceptives with an estrogen component (combination OC, vaginal ring and the transdermal contraceptive) contained ethinyl estradiol, but there were eight different progestin types used solely or in combination with ethinyl estradiol, including desogestrel, drospirenone, levonorgestrel, norelgestromin, norethisterone, lynestronol, medroxyprogesterone and etonogestrel. Any exposures with fewer than 10 exposed cases we combined into a single 'other' category (Supplementary Table S1 ).
Although our primary interest was to explore the association between exposure in early pregnancy and offspring overweight or obesity, we also characterized exposure into discrete windows of hormonal contraceptive exposure according to last date of use relative to conception, for example, 12 to 44 months before, 4 to 41 months before, 1 to 40 months before and 0-12 weeks after. These periods of exposure were selected as they correspond to possibly distinct developmental periods of susceptibility, specifically the primordial follicular phase (follicle-stimulating hormone independent) (12 to 4 months before conception), the secondary to antral phase of follicular development (follicle-stimulating hormone dependent) (4 to 1 month before conception), the emergence of a dominant follicle and release of the oocyte (1 month before conception) and post conception, early pregnancy (weeks 0-12), when endogenous levels of estradiol and progesterone are still relatively low and exogenous sources of exposure may contribute a relatively higher dose (relative to endogenous levels). 39 Date of conception was estimated by subtracting 17 days 40 from the number of days of gestational length at birth (to account for the follicular phase before conception) and then subtracting this value from the date of birth. We used the last menstrual period-based estimated gestational length unless the last menstrual period-based gestational length was missing (5.1%) or ⩾ 2 weeks from the ultrasound-based estimate of gestational length (5.2%), in which case we used the ultrasound-based measure. 41 We then constructed an exposure window for each hormonal contraceptive prescription filled using the date that the prescription was filled and the number of defined daily doses dispensed (day's supply). Most OCs were dispensed in a 3-month supply (82%) or a 6-month supply (15%). For pregnancies with more than one type of hormonal contraceptive prescribed, we assigned exposure type according to the type of contraceptive used closest to the estimated date of conception. Because many women may choose to stop taking their hormonal contraceptive to achieve conception, we characterized women as exposed in early pregnancy only if they reported that the pregnancy was unplanned and had ⩾ 1 day supply of hormonal contraceptive at or after the day of conception.
Offspring overweight or obesity was defined by first calculating the offspring body mass index (BMI) (kg m −2 ) at age 3 years from questionnaire-reported height and weight measures. In Norway, families are provided a health card to record information about their children. Mothers were asked to transcribe the health-care data on height, weight and date onto a MoBa questionnaire when the children were 3 years old. Offspring were characterized as overweight or obese using the age-and sex-specific cut points developed by the International Obesity Taskforce (17.89 kg m − 2 for boys and 17.56 kg m − 2 for girls). 42 To evaluate the accuracy of the child height and weight data, we conducted a validation substudy. We assessed the correlation between BMI obtained from the questionnaire and BMI based on measures taken for the Bergen Growth Study. 43 The correlation was examined among measures obtained within 90 days of one another. 44 Covariate selection was informed through construction of a directed acyclic graph. 45 The adjustment factors selected (and data source) were maternal age (MBRN) (14-19, 20-29, 30-39 and 40-49) , prepregnancy BMI (MoBa pregnancy questionnaire) (kg m − 2 ) (o 18.5, 18.5-24.9 and ⩾ 25.0), parity (MBRN) (0, 1 and ⩾ 2), smoking (composite from MoBa questionnaires and the MBRN) (none, quit during pregnancy and smoker) and education (MoBa pregnancy questionnaire) (44 years of university or technical, 4-year university or technical degree, 3 years of college preparatory high school, 3 years of technical high school, 1-2 years of high school, o9 years of secondary school and other).
Primary analyses
Our primary analyses were concerned with assessing the association between early pregnancy hormonal contraceptive exposure, as compared with no use of a hormonal contraceptive in early pregnancy or the 12 months before pregnancy, and offspring overweight or obesity. We used generalized linear models with a logit link and generalized estimation equations with an independent correlation matrix 46 to estimate robust standard errors and account for lack of independence between siblings. We used similar models to assess the association between hormonal contraceptive use before conception and offspring overweight or obesity. Finally, we evaluated the association between hormonal contraceptive use with BMI z-score, calculated from the World Health Organization growth standards for BMI. 47 
Subgroup analyses
In subgroup analyses, we explored the association between route of administration and type of progestin agent and offspring overweight or obesity. We also explored whether there was evidence of interaction between hormonal contraceptive use and offspring sex, maternal prepregnancy overweight/obese status (⩾25.0 kg m − 2 ; yes/no) or maternal pre-pregnancy weight using interaction terms. A priori, we considered a P-value o 0.20 as evidence of potential interaction. 48 Given evidence of possible interaction, we examined stratum-specific estimates. All analyses were conducted using SAS v9.3 (SAS Inc., Cary, NC, USA).
Sensitivity analyses
We conducted several sensitivity analyses to address the potential for residual confounding or confounding by indication (use of different comparator groups and additional adjustment factors), the potential for selection bias from loss to follow-up (use of both multiple imputation and inverse probability weighting) and the potential for exposure misclassification (consideration of self-reported use of hormonal contraceptives). We also assessed whether a log-binomial model, for estimating relative risks, generated estimates that were materially different from estimates obtained in the logit model estimating odds ratios. The methods for these analyses are described in Supplementary Information, with supporting details provided in Supplementary Tables S1-S3 .
RESULTS
In general, compared with all MoBa pregnancies with baseline data collected in pregnancy and at birth, the pregnancies included in the final study sample were to women who were older, less parous, more educated and less likely to have smoked in pregnancy (Table 1) . At 36 months of age, 2653 (13.1%) children in the analysis met the International Obesity Taskforce definitions for overweight or obese. We identified 3392 pregnancies exposed 12 to 44 months before, 2541 4 to 41 months before, 2997 1 to 40 month before and 567 0-12 weeks after conception. For the validation substudy, 77 children had height and weight data at age 3 collected in both MoBa and the Bergen Growth Study. These data were obtained no more than 90 days apart from the respective studies (mean difference: 32 days, standard deviation 33 days). The correlation of BMI between the two sources of data was high (Pearson's r = 0.86, 95% confidence interval (CI): 0.81, 0.90) and consistent with the expected correlation between BMI calculated from serial measures of height and weight in young children. 44 Primary analyses In early pregnancy, the combination OC was weakly, inversely associated with offspring overweight or obesity at age 3 (adjusted odds ratio (aOR): 0.75, 95% CI: 0.53, 1.08). The progestin-only OC was weakly, positively associated with overweight or obesity (aOR: 1.26, 95% CI: 0.79, 2.02) ( Table 2 ). Use of a hormonal contraceptive before pregnancy was generally not associated with overweight or obesity, with the exception of use of a vaginal ring-type hormonal contraceptive, which was inversely associated, particularly for exposure estimated to have occurred 1 to 40 months before conception (aOR: 0.60, 95% CI: 0.35, 1.04) ( Table 2 ). Data were too sparse to evaluate the association between early pregnancy use of the vaginal ring and subsequent offspring overweight or obesity. The direction of the estimates obtained when modeling BMI z-score as a continuous outcome were similar to those obtained when modeling BMI as a dichotomous outcome (data not shown).
Subgroup analyses
Among combination OC users, the association with overweight or obesity was similar across combination OCs with differing progestin components (Supplementary Tables S4-S7 ). In early pregnancy only, the desogestrel progestin-only OC was moderately associated with offspring overweight or obesity (aOR: 1.87, 95% CI: 1.06, 3.32) (Supplementary Table S4 ).
For early pregnancy use of a combination OC, there was a weak evidence of effect modification by offspring sex or maternal prepregnancy BMI. For exposure to the combination OC in early pregnancy, the observed association with overweight or obesity was present only in males (aOR: 0.56, 95% CI: 0.32, 0.97 in males vs aOR: 0.98, 95% CI: 0.63, 1.53 in females). The magnitude of association observed for use of the combination OC was also stronger in women characterized as normal BMI (BMI o25.0 kg m Table S8 ). There was no evidence of interaction between hormonal contraceptive use (of any type) and maternal prepregnancy weight (P for interaction term 40.20).
Sensitivity analyses
In early pregnancy, for the analyses evaluating the use of different comparator groups, the inverse association between the combination OC and offspring overweight or obesity was robust to restricting the comparator population to unplanned pregnancies (aOR: 0.70, 95% CI: 0.48, 1.02; Table 3 ). This inverse relationship was also materially unchanged when comparing early pregnancy combination OC users with former users of the combination OC and when comparing the combination OC users with the progestin-only OC users (aOR: 0.75, 95% CI: 0.52, 1.06) (Table 3) . Similarly, the relationship between progestin use in early pregnancy and offspring overweight or obesity was robust to choice of comparator groups (Table 3) .
The estimate comparing vaginal ring use to the combination OC (within 1 month before conception) was aOR 0.59 (95% CI: 0.33, 1.03) and consistent with estimates obtained when comparing vaginal ring users with non-users of a hormonal contraceptive (aOR: 0.60, 95% CI: 0.35, 1.04).
The magnitude of the estimates from models employing multiple imputation were somewhat attenuated (aOR: 0.85, 95% CI: 0.66, 1.11 for the combination OC) compared with those obtained in the primary analyses (aOR: 0.75, 95% CI: 0.53, 1.06), whereas estimates obtained using inverse probability weighting were somewhat strengthened (aOR: 0.68, 95% CI: 0.49, 0.99 for the combination OC) (Supplementary Tables S9 and S10). Characterising exposure by self-reported use in early pregnancy, as reported on the questionnaire administered during pregnancy, also attenuated the estimates observed and introduced additional imprecision (aOR: 0.88, 95% CI: 0.57, 1.35 for use of the combination OC and aOR: 1.15, 95% CI: 0.58, 2.28 for use of the progestin-only OC) (data not shown). Adjustment for diabetes type 1 or 2, age in 5-year increments, income and maternal weight did not substantively change the estimates (data not shown). Estimates obtained using a log-binomial model were also not materially different (combination OC risk ratio: 0.78 (95% CI: 0.57, 1.82) and progestin-only OC risk ratio: 1.23 (95% CI: 0.83, 1.82) for early pregnancy use). Hormonal contraceptives with o10 exposed cases were combined into an 'other' category. 
DISCUSSION
In our primary analysis of the association between early pregnancy hormonal contraceptive use and offspring overweight or obesity, we found that use of a combination OC was weakly, inversely associated with offspring overweight or obesity at age 3. Use of the progestin-only OC in early pregnancy was weakly, positively associated with offspring overweight or obesity. A moderate positive association for early pregnancy progestin-only OC use was observed for desogestrel. With the exception of an inverse association for the vaginal ring, there was no association with use of a hormonal contraceptive before pregnancy and offspring overweight or obesity. The absence of an association with use before pregnancy suggests that any developmental effect may be the result of a direct effect on the embryo and fetus, as opposed to changes to follicular or oocyte development. The relevance of timing of use was further supported by an evaluation of selfreported duration that was unrelated to offspring overweight or obesity (data not shown). All of the associations were qualitatively unchanged with selection of different comparator groups, suggesting that the characteristics of women using the contraceptive were not contributing to the estimates observed. The sensitivity analyses indicated that the results could have been affected somewhat by out-selection bias, but the direction of the bias was unclear. The sensitivity analyses also showed that results were attenuated when based on self-reported hormonal contraceptive use. Selfreported data, however, lacked the detail of the NorPD data, and progestin-specific associations could not be ascertained.
In experimental animal models, in utero and neonatal exposure to estrogenic agents (diethylstilbestrol and 17β-estradiol) results in an initial period of depressed growth, followed by increasing adiposity at follow-up. 6, 16 Although the timing of exposure for these animal studies is somewhat different (from conception through birth for pregnancy and in early neonatal life), the weak, inverse association with the combination pill in the present study may be congruent with observations of an initial period of depressed growth in these experimental studies. The evidence for depressed growth from hormonal contraceptives in human studies has been mixed, with some studies indicating no association with birthweight or low birthweight and others indicating a weak, positive association with low birthweight. The number of exposed pregnancies in these studies has been small and unable to differentiate between contraceptive formulations. [49] [50] [51] [52] Additional follow-up of the MoBa cohort will allow investigation of associations at later ages to determine whether the growth pattern exhibited in animal models is relevant in humans.
We observed differences in association depending on the type of contraceptive and progestin used. The agents in different hormonal contraceptives vary with respect to their biding affinities for androgen, progestogen and estrogen receptors. Some exert androgenic properties, others antiandrogenic properties. 15 To our knowledge, studies of offspring adiposity or growth following exposure to progestogenic compounds during early fetal development have not been conducted in animals or humans. However, endogenous serum progesterone levels in pregnancy have been positively associated with offspring birthweight 53, 54 and birthweight has been associated with offspring weight at follow-up. 55 Fetal exposure to androgenic agents has resulted in metabolic abnormalities, including a polycystic ovarian syndromelike phenotype in animal models. 12 Unopposed by ethinyl estradiol, desogestrel has high progestational and moderate androgenic activity relative to other progestin types, but when desogestrel is present in combination with ethinyl estradiol, the progestational and androgenic activities are substantively reduced. 15 Norethisterone is only weakly androgenic. This property may explain the difference in association observed between desogestrel and norethisterone progestin-only contraceptives in this study.
The inverse association between use of the vaginal ring and offspring overweight or obesity may be attributable to the pharmacokinetic properties of the vaginal ring. The vaginal ring contains etonogestrel and ethinyl estradiol. Hormonal constituents of the vaginal ring are absorbed through the vaginal epithelium and provide steady release of etonogestrel and ethinyl estradiol for the 3-week period after the ring is inserted. 15 Pharmacokinetic studies comparing the vaginal ring with the combination OC indicate that the dose of ethinyl estradiol, as measured in blood serum and represented by the area under the curve, is lower than that of doses experienced in combination OC users. 56 The agents in the vaginal ring do not experience first pass metabolism. The ring provides a consistent release of hormones unaffected by dietary or gastrointestinal factors and is less subject to fluctuation in delivered dose when compared with oral or transdermal-administered forms of contraception. 57 Sparse data limited the ability to assess variation in effects by different progestin types in early pregnancy. We found possible evidence of effect modification by offspring sex and maternal prepregnancy BMI for the combination OC; however, sample size limitations may have also precluded the ability to detect effect modification for the progestin-only formulation. The possible effect modification observed for early pregnancy is consistent with animal data, suggesting that developmental effects of estrogenic compounds may be stronger among male offspring. 16 The associations observed could be attributable to residual confounding or confounding by indication. Women may be prescribed different contraceptive formulations based on factors for which we cannot control in our data. Notwithstanding, estimates obtained from sensitivity analyses, conducted to assess the potential for confounding by indication, were robust to choice of comparator group. Use of methods to explore the potential for bias from loss to follow-up is effective only insofar as we have correctly assumed that we were able to successfully impute missing values from the covariates in our imputation models (multiple imputation approach) or correctly predict the probability of staying in the study from the covariates in our predicted probability models for generating weights (inverse probability weighting approach). There was also a potential for misclassification of the timing of exposure.
The overall proportion of overweight or obese children at age 3 in this study (13.1%) is relatively consistent with national prevalence estimates for overweight or obesity at age 3 that were obtained from height and weight data collected by research staff (11.3%). 58 Nonetheless, BMI is less specific for identifying clinically relevant adiposity in children when compared with other measures of assessing childhood adiposity. 59 Overweight and obesity may be influenced by developmental exposure to exogenous sex hormones. The present data suggest that pharmacologic sex hormone agents may be associated with offspring overweight or obesity at age 3. The direction of the relationships appears contingent upon hormone formulation. Little is known about long-term, formulation-specific effects on offspring weight status.
Data from experiments on animals suggest that early life exposure to hormonally active agents may affect offspring growth. Given the evidence that early life anthropometric indicators are associated with adult adiposity, 2,3 the investigation of determinants of early life anthropometrics is warranted. The results presented provide support for the assertion that in utero exposure to hormonally active agents, during developmentally sensitive periods, may contribute to alterations in offspring growth.
